Outlining Advances Made in Ovarian Cancer in Oklahoma City

We recently traveled to Oklahoma City, Oklahoma for a State of the Science Summit™ on ovarian cancer. At the meeting, faculty from Stephenson Cancer Center shed light on the necessity of PARP inhibitors in recurrent ovarian cancer, emerging strategies for PARP inhibitor resistance, and explained why neoadjuvant chemotherapy could be a safer alternative for certain patients. Additionally, faculty shared their hope for effective screening modalities, explained how to navigate among maintenance options in advanced-stage disease, and projected the impact of immunotherapy.